Production (Stage)
GenSight Biologics S.A.
GSGTF
$0.24
-$0.08-25.00%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 46.58% | 36.99% | 27.68% | 14.21% | 1.80% |
| Total Depreciation and Amortization | -51.41% | -5.36% | 83.69% | 98.55% | 110.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 71.75% | 101.19% | 116.51% | 76.52% | 5.98% |
| Change in Net Operating Assets | -64.36% | -25.97% | 204.04% | 207.00% | 162.04% |
| Cash from Operations | 47.52% | 49.52% | 50.93% | 37.06% | 25.03% |
| Capital Expenditure | 90.74% | 88.97% | 88.71% | 93.85% | 95.96% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -91.76% | -82.22% | -75.57% | -59.10% | -47.33% |
| Cash from Investing | -91.85% | -80.61% | -70.02% | -28.96% | 24.19% |
| Total Debt Issued | -- | -81.26% | -67.12% | -31.20% | 31.31% |
| Total Debt Repaid | -54.56% | 61.97% | 90.79% | 84.19% | 78.43% |
| Issuance of Common Stock | 253.73% | 576.74% | 5,492.69% | 5,867.10% | 7,814.00% |
| Repurchase of Common Stock | 72.73% | -49.49% | -- | 9.09% | 59.09% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 900.97% | 304.69% | 197.85% | 138.70% | 83.18% |
| Cash from Financing | -14.65% | 37.71% | 126.03% | 297.74% | 10,702.10% |
| Foreign Exchange rate Adjustments | -346.46% | -187.89% | -54.17% | 467.40% | 158.93% |
| Miscellaneous Cash Flow Adjustments | -- | -200.00% | -200.00% | -200.00% | -- |
| Net Change in Cash | 103.80% | 119.99% | 126.56% | 95.25% | 74.40% |